Volume | 298,572 |
|
|||||
News | - | ||||||
Day High | 3.60 | Low High |
|||||
Day Low | 3.14 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
ProKidney Corporation | PROK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.57 | 3.14 | 3.60 | 3.19 | 3.60 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,319 | 298,572 | US$ 3.35 | US$ 998,824 | - | 1.12 - 13.51 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:11:58 | formt | 150 | US$ 3.50 | USD |
ProKidney Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.18B | 235.43M | - | 0 | -35.47M | -0.15 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ProKidney News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PROK Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.22 | 4.2575 | 3.00 | 3.39 | 588,575 | -0.72 | -17.06% |
1 Month | 2.65 | 4.44 | 2.60 | 3.74 | 786,740 | 0.85 | 32.08% |
3 Months | 1.38 | 4.44 | 1.35 | 2.68 | 800,178 | 2.12 | 153.62% |
6 Months | 1.80 | 4.44 | 1.18 | 2.18 | 698,373 | 1.70 | 94.44% |
1 Year | 11.90 | 13.51 | 1.12 | 3.50 | 698,074 | -8.40 | -70.59% |
3 Years | 9.40 | 14.19 | 1.12 | 4.49 | 425,612 | -5.90 | -62.77% |
5 Years | 9.40 | 14.19 | 1.12 | 4.49 | 425,612 | -5.90 | -62.77% |
ProKidney Description
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. |